Race Oncology is a specialty pharmaceutical company focused on rediscovering and rescuing life-saving drugs that can deliver early commercial milestones. Race Oncology’s first asset is Bisantrene, a small molecule Chemotherapy drug that has been evaluated clinically for Acute Myeloid Leukaemia (AML).
|18/07/2018||FDA Grants Bisantrene Rare Paediatric Disease Designation||Download|
|13/07/2018||Appendix 3B-Issue of Options||Download|
|02/07/2018||Expiry of Unlisted Options||Download|
|02/07/2018||Performance Share Milestones Met||Download|
|26/06/2018||Bisantrene poster presented at French Leukaemia Conference||Download|
|22/06/2018||Release of Securities from Escrow||Download|